Prot #D3251C00014: A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary

Project: Research project

Project Details

StatusActive
Effective start/end date10/14/20 → 10/14/26

Funding

  • AstraZeneca Pharmaceuticals LP ((OE) Prot #D3251C00014 AMD A-75845)